688197 首药控股
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-17.002-16.662-28.777-195.939-206.150
总资产报酬率 ROA (%)-15.259-15.391-25.610-123.473-166.958
投入资产回报率 ROIC (%)-16.895-16.570-28.483-191.191-236.048

边际利润分析
销售毛利率 (%)100.00097.87199.37199.93299.941
营业利润率 (%)-4,209.951-3,548.333-9,518.597-1,116.806-4,696.104
息税前利润/营业总收入 (%)-4,341.321-3,911.122-10,613.206-1,122.645-4,734.059
净利润/营业总收入 (%)-4,209.951-3,548.792-9,512.739-1,111.996-4,703.466

收益指标分析
经营活动净收益/利润总额(%)107.612107.506114.578112.123101.233
价值变动净收益/利润总额(%)-7.425-3.827-0.6550.000-0.629
营业外收支净额/利润总额(%)0.0000.013-0.062-0.4330.157

偿债能力分析
流动比率 (X)7.07610.89813.4950.6877.170
速动比率 (X)7.06210.89513.4690.6597.047
资产负债率 (%)12.5668.1977.13797.41917.072
带息债务/全部投入资本 (%)0.4850.2210.485-3.823--
股东权益/带息债务 (%)20,408.00745,149.97320,485.261-803.100-1,919.500
股东权益/负债合计 (%)695.8151,119.9701,301.0842.650485.764
利息保障倍数 (X)33.04610.7949.644105.421154.746

营运能力分析
应收账款周转天数 (天)0.0000.000374.34352.4840.000
存货周转天数 (天)--4,113.77458,806.56685,920.5990.000